Items where authors include "Weinblatt, ME"

Article

Smolen, JS, Kang, YM, Yoo, WH et al. (7 more authors) (2020) Radiographic Progression Based on Baseline Characteristics From TNF Inhibitor Biosimilar Studies in Patients With Rheumatoid Arthritis. Arthritis Research and Therapy, 22. 188. ISSN 1478-6354

Smolen, JS, Choe, J-Y, Weinblatt, ME et al. (7 more authors) (2020) Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD Open, 6 (1). e001096. ISSN 2056-5933

Traylor, M, Knevel, R, Cui, J et al. (17 more authors) (2019) Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases. PLoS ONE, 14 (10). ARTN: e022. ISSN 1932-6203

Weinblatt, ME, Bingham, CO, Burmester, G-R et al. (9 more authors) (2017) A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis and Rheumatology, 69 (10). pp. 1937-1948. ISSN 2326-5191

Emery, P, Bingham III, CO, Burmester, GR et al. (11 more authors) (2017) Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Annals of the Rheumatic Diseases, 76 (1). pp. 96-104. ISSN 0003-4967

Bykerk, VP, Emery, P, Weinblatt, ME et al. (7 more authors) (2016) PMS82 – Clinical Responses and Improvements in Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol. Value in Health. ISSN 1098-3015

Emery, P, Bingham III, CO, Burmester, GR et al. (11 more authors) (2016) Response to: ‘Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!’ by Boers. Annals of the Rheumatic Diseases, 75 (10). e69. ISSN 0003-4967

Weinblatt, ME, Fleischmann, R, van Vollenhoven, RF et al. (8 more authors) (2015) Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Research and Therapy, 17. 325. ISSN 1478-6354

Weinblatt, ME, Mease, P, Mysler, E et al. (7 more authors) (2015) The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis and Rheumatology, 67 (10). pp. 2591-2600. ISSN 2326-5191